Gene |
Condition |
AARS2 |
Combined oxidative phosphorylation deficiency 8; Leukoencephalopathy, progressive, with ovarian failure |
AASS |
Hyperlysinemia |
ABAT |
GABA-transaminase deficiency |
ABCB6 |
Dyschromatosis universalis hereditaria 3; Microphthalmia, isolated, with coloboma 7; Pseudohyperkalemia, familial, 2, due to red cell leak; [Blood group, Langereis system] |
ABCB7 |
Anemia, sideroblastic, with ataxia |
ABCD1 |
Adrenoleukodystrophy; Adrenomyeloneuropathy, adult |
ABCD3 |
?Bile acid synthesis defect, congenital, 5 |
ACACA |
Acetyl-CoA carboxylase deficiency |
ACAD8 |
Isobutyryl-CoA dehydrogenase deficiency |
ACAD9 |
Mitochondrial complex I deficiency due to ACAD9 deficiency |
ACADM |
Acyl-CoA dehydrogenase, medium chain, deficiency of |
ACADS |
Acyl-CoA dehydrogenase, short-chain, deficiency of |
ACADSB |
2-methylbutyrylglycinuria |
ACADVL |
VLCAD deficiency |
ACAT1 |
Alpha-methylacetoacetic aciduria |
ACO2 |
Infantile cerebellar-retinal degeneration; Optic atrophy 9 |
ACOX1 |
Mitchell syndrome; Peroxisomal acyl-CoA oxidase deficiency |
ACSF3 |
Combined malonic and methylmalonic aciduria |
ACSL4 |
Intellectual developmental disorder, X-linked 63 |
AFG3L2 |
Spastic ataxia 5, autosomal recessive; Spinocerebellar ataxia 28 |
AGK |
Cataract 38, autosomal recessive; Sengers syndrome |
AGXT |
Hyperoxaluria, primary, type 1 |
AIFM1 |
Combined oxidative phosphorylation deficiency 6; Cowchock syndrome; Deafness, X-linked 5 |
AK2 |
Reticular dysgenesis |
ALAS2 |
Anemia, sideroblastic, 1; Protoporphyria, erythropoietic, X-linked |
ALDH18A1 |
Cutis laxa, autosomal dominant 3; Cutis laxa, autosomal recessive, type IIIA; Spastic paraplegia 9A, autosomal dominant; Spastic paraplegia 9B, autosomal recessive |
ALDH2 |
Alcohol sensitivity, acute; {Esophageal cancer, alcohol-related, susceptibility to}; {Hangover, susceptibility to}; {Sublingual nitroglycerin, susceptibility to poor response to} |
ALDH3A2 |
Sjogren-Larsson syndrome |
ALDH4A1 |
Hyperprolinemia, type II |
ALDH5A1 |
Succinic semialdehyde dehydrogenase deficiency |
ALDH6A1 |
Methylmalonate semialdehyde dehydrogenase deficiency |
ALDH7A1 |
Epilepsy, pyridoxine-dependent |
AMACR |
Alpha-methylacyl-CoA racemase deficiency; Bile acid synthesis defect, congenital, 4 |
AMT |
Glycine encephalopathy |
APTX |
Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia |
ATIC |
AICA-ribosiduria due to ATIC deficiency |
ATP5F1A |
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4; Combined oxidative phosphorylation deficiency 22 |
ATP5F1E |
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3 |
ATP7B |
Wilson disease |
ATPAF2 |
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1 |
ATXN2 |
Spinocerebellar ataxia 2; {Amyotrophic lateral sclerosis, susceptibility to, 13}; {Parkinson disease, late-onset, susceptibility to} |
AUH |
3-methylglutaconic aciduria, type I |
BAX |
Colorectal cancer, somatic; T-cell acute lymphoblastic leukemia, somatic |
BCKDHA |
Maple syrup urine disease, type Ia |
BCKDHB |
Maple syrup urine disease, type Ib |
BCKDK |
Branched-chain keto acid dehydrogenase kinase deficiency |
BCL2 |
Leukemia/lymphoma, B-cell, 2 |
BCS1L |
Mitochondrial complex III deficiency, nuclear type 1; Bjornstad syndrome; GRACILE syndrome; Leigh syndrome |
BOLA3 |
Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia |
BRIP1 |
Fanconi anemia, complementation group J; {Breast cancer, early-onset, susceptibility to} |
BTD |
Biotinidase deficiency |
C12orf65 |
Combined oxidative phosphorylation deficiency 7; Spastic paraplegia 55, autosomal recessive |
C19orf12 |
Neurodegeneration with brain iron accumulation 4; Spastic paraplegia 43, autosomal recessive |
CA5A |
Hyperammonemia due to carbonic anhydrase VA deficiency |
CARS2 |
Combined oxidative phosphorylation deficiency 27 |
CASP8 |
?Autoimmune lymphoproliferative syndrome, type IIB; Hepatocellular carcinoma, somatic; {Breast cancer, protection against}; {Lung cancer, protection against} |
CAT |
Acatalasemia |
CAVIN1 |
Lipodystrophy, congenital generalized, type 4 |
CEL |
Maturity-onset diabetes of the young, type VIII |
CHCHD10 |
?Myopathy, isolated mitochondrial, autosomal dominant; Frontotemporal dementia and/or amyotrophic lateral sclerosis 2; Spinal muscular atrophy, Jokela type |
CISD2 |
Wolfram syndrome 2 |
CLPB |
3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia |
CLPP |
Perrault syndrome 3 |
COA5 |
Cardioencephalomyopathy, fatal infantile; due to cytochrome c oxidase deficiency 3 |
COA6 |
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4 |
COA8 |
Mitochondrial complex IV deficiency |
COASY |
Neurodegeneration with brain iron accumulation 6; Pontocerebellar hypoplasia, type 12 |
COMT |
{Panic disorder, susceptibility to}; {Schizophrenia, susceptibility to} |
COQ2 |
Coenzyme Q10 deficiency, primary, 1; Multiple system atrophy, susceptibility to |
COQ4 |
Coenzyme Q10 deficiency, primary, 7 |
COQ6 |
Coenzyme Q10 deficiency, primary, 6 |
COQ8A |
Coenzyme Q10 deficiency, primary, 4 |
COQ8B |
Nephrotic syndrome, type 9 |
COQ9 |
Coenzyme Q10 deficiency, primary, 5 |
COQ9 |
Coenzyme Q10 deficiency, primary, 5 |
COX10 |
Mitochondrial complex IV deficiency; Leigh syndrome due to mitochondrial COX4 deficiency |
COX14 |
Mitochondrial complex IV deficiency |
COX15 |
Leigh syndrome due to cytochrome c oxidase deficiency; Cardioencephalomyopathy, fatal infantile due to cytochrome c oxidase deficiency 2 |
COX20 |
Mitochondrial complex IV deficiency |
COX4I2 |
Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis |
COX6A1 |
Charcot-Marie-Tooth disease, recessive intermediate D |
COX6A2 |
Mitochondrial complex IV deficiency |
COX6B1 |
Mitochondrial complex IV deficiency |
COX7B |
Linear skin defects with multiple congenital anomalies 2 |
COX8A2 |
Mitochondrial complex IV deficiency |
CPOX |
Coproporphyria; Harderoporphyria |
CPS1 |
Carbamoylphosphate synthetase I deficiency; {Pulmonary hypertension, neonatal, susceptibility to} |
CPT1A |
CPT deficiency, hepatic, type IA |
CPT1C |
?Spastic paraplegia 73, autosomal dominant |
CPT2 |
CPT II deficiency, infantile; CPT II deficiency, lethal neonatal; CPT II deficiency, myopathic, stress-induced |
CRBN |
Mental retardation, autosomal recessive 2 |
CYB5A |
Methemoglobinemia and ambiguous genitalia |
CYB5R3 |
Methemoglobinemia, type I; Methemoglobinemia, type II |
CYC1 |
Mitochondrial complex III deficiency, nuclear type 6 |
CYCS |
Thrombocytopenia 4 |
CYP11A1 |
Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete |
CYP11B1 |
Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency; Aldosteronism, glucocorticoid-remediable |
CYP11B2 |
Aldosterone to renin ratio raised; Hypoaldosteronism, congenital, due to CMO I deficiency; Hypoaldosteronism, congenital, due to CMO II deficiency; {Low renin hypertension, susceptibility to} |
CYP24A1 |
Hypercalcemia, infantile, 1 |
CYP27A1 |
Cerebrotendinous xanthomatosis |
CYP27B1 |
Vitamin D-dependent rickets, type I |
D2HGDH |
D-2-hydroxyglutaric aciduria |
DARS2 |
Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation |
DBT |
Maple syrup urine disease, type II |
DGUOK |
Mitochondrial DNA depletion syndrome 3 (hepatocerebral type); Portal hypertension, noncirrhotic; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4 |
DHCR24 |
Desmosterolosis |
DHODH |
Miller syndrome |
DHTKD1 |
?Charcot-Marie-Tooth disease, axonal, type 2Q; Alpha-aminoadipic and alpha-ketoadipic aciduria |
DIABLO |
Deafness, autosomal dominant 64 |
DLAT |
Pyruvate dehydrogenase E2 deficiency |
DLD |
Dihydrolipoamide dehydrogenase deficiency |
DMGDH |
Dimethylglycine dehydrogenase deficiency |
DMPK |
Myotonic dystrophy 1 |
DNA2 |
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 6; Seckel syndrome 8 |
DNAJC19 |
3-methylglutaconic aciduria, type V |
DNAJC3 |
?Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus |
DNM1L |
Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1; Optic atrophy 5 |
EARS2 |
Combined oxidative phosphorylation deficiency 12 |
ECHS1 |
Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency |
ELAC2 |
Combined oxidative phosphorylation deficiency 17 |
EPHX2 |
{Hypercholesterolemia, familial, due to LDLR defect, modifier of} |
ETFA |
Glutaric acidemia IIA |
ETFB |
Glutaric acidemia IIB |
ETFDH |
Glutaric acidemia IIC |
ETHE1 |
Ethylmalonic encephalopathy |
FAH |
Tyrosinemia, type I |
FARS2 |
Combined oxidative phosphorylation deficiency 14; Spastic paraplegia 77, autosomal recessive |
FASTKD2 |
Mitochondrial complex IV deficiency |
FBP1 |
Fructose-1,6-bisphosphatase deficiency |
FBXL4 |
Mitochondrial DNA depletion syndrome 13 |
FDX2 |
Mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy |
FECH |
Protoporphyria, erythropoietic, 1 |
FH |
Fumarase deficiency; Leiomyomatosis and renal cell cancer |
FKBP10 |
Bruck syndrome 1; Osteogenesis imperfecta, type XI |
FLAD1 |
Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency |
FOXRED1 |
Leigh syndrome due to mitochondrial complex I deficiency; Mitochondrial complex I deficiency |
FTH1 |
?Hemochromatosis, type 5 |
FXN |
Friedreich ataxia; Friedreich ataxia with retained reflexes |
G6PC |
Glycogen storage disease Ia |
GAMT |
Cerebral creatine deficiency syndrome 2 |
GARS1 |
Neuronopathy, distal hereditary motor, type VA; Charcot-Marie-Tooth disease, type 2D |
GATM |
Cerebral creatine deficiency syndrome 3 |
GCDH |
Glutaricaciduria, type I |
GDAP1 |
Charcot-Marie-Tooth disease, axonal, type 2K; Charcot-Marie-Tooth disease, axonal, with vocal cord paresis; Charcot-Marie-Tooth disease, recessive intermediate, A; Charcot-Marie-Tooth disease, type 4A |
GFER |
Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay |
GFM1 |
Combined oxidative phosphorylation deficiency 1 |
GFM2 |
Combined oxidative phosphorylation deficiency 39 |
GK |
Glycerol kinase deficiency |
GLDC |
Glycine encephalopathy |
GLRX5 |
Spasticity, childhood-onset, with hyperglycinemia; Anemia, sideroblastic, 3, pyridoxine-refractory |
GLUD1 |
Hyperinsulinism-hyperammonemia syndrome |
GLYCTK |
D-glyceric aciduria |
GPI |
Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency |
GPT2 |
Neurodevelopmental disorder with microcephaly and spastic paraplegia |
GPX1 |
Hemolytic anemia due to glutathione peroxidase deficiency |
GRHPR |
Hyperoxaluria, primary, type II |
GSR |
Hemolytic anemia due to glutathione reductase deficiency |
GTPBP3 |
Combined oxidative phosphorylation deficiency 23 |
GYS2 |
Glycogen storage disease 0, liver |
HADH |
3-hydroxyacyl-CoA dehydrogenase deficiency; Hyperinsulinemic hypoglycemia, familial, 4 |
HADHA |
LCHAD deficiency; Trifunctional protein deficiency |
HAMP |
Hemochromatosis, type 2B |
HARS2 |
Perrault syndrome 2 |
HAX1 |
Neutropenia, severe congenital 3, autosomal recessive |
HCCS |
Linear skin defects with multiple congenital anomalies 1 |
HIBCH |
3-hydroxyisobutryl-CoA hydrolase deficiency |
HINT1 |
Neuromyotonia and axonal neuropathy, autosomal recessive |
HK1 |
Hemolytic anemia due to hexokinase deficiency; Neurodevelopmental disorder with visual defects and brain anomalies; Neuropathy, hereditary motor and sensory, Russe type; Retinitis pigmentosa 79 |
HLCS |
Holocarboxylase synthetase deficiency |
HLCS |
Holocarboxylase synthetase deficiency |
HMBS |
Porphyria, acute intermittent; Porphyria, acute intermittent, nonerythroid variant |
HMGCL |
HMG-CoA lyase deficiency |
HMGCS2 |
HMG-CoA synthase-2 deficiency |
HOGA1 |
Hyperoxaluria, primary, type III |
HSD17B10 |
HSD10 mitochondrial disease |
HSD17B4 |
D-bifunctional protein deficiency; Perrault syndrome 1 |
HSD3B2 |
Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency |
HSPA9 |
Anemia, sideroblastic, 4; Even-plus syndrome |
HSPD1 |
Leukodystrophy, hypomyelinating, 4; Spastic paraplegia 13, autosomal dominant |
HTRA2 |
3-methylglutaconic aciduria, type VIII |
IDH2 |
D-2-hydroxyglutaric aciduria 2 |
IDH3B |
Retinitis pigmentosa 46 |
ISCU |
Myopathy with lactic acidosis, hereditary |
IVD |
Isovaleric acidemia |
KARS1 |
?Charcot-Marie-Tooth disease, recessive intermediate, B; Deafness, autosomal recessive 89; Deafness, congenital, and adult-onset progressive leukoencephalopathy; Leukoencephalopathy, progressive, infantile-onset, with or without deafness |
KIF1B |
Charcot-Marie-Tooth disease, type 2A1; Pheochromocytoma; {Neuroblastoma, susceptibility to, 1} |
KRT5 |
Dowling-Degos disease 1; Epidermolysis bullosa simplex 2A, generalized severe; Epidermolysis bullosa simplex 2B, generalized intermediate; Epidermolysis bullosa simplex 2C, localized; Epidermolysis bullosa simplex 2D, generalized, intermediate or severe, autosomal recessive; Epidermolysis bullosa simplex 2E, with migratory circinate erythema; Epidermolysis bullosa simplex 2F, with mottled pigmentation |
L2HGDH |
L-2-hydroxyglutaric aciduria |
LONP1 |
CODAS syndrome |
LRPPRC |
Leigh syndrome, French-Canadian type |
MAOA |
Brunner syndrome; {Antisocial behavior} |
MCCC1 |
3-Methylcrotonyl-CoA carboxylase 1 deficiency |
MCCC2 |
3-Methylcrotonyl-CoA carboxylase 2 deficiency |
MCEE |
Methylmalonyl-CoA epimerase deficiency |
MFN2 |
Charcot-Marie-Tooth disease, axonal, type 2A2A; Charcot-Marie-Tooth disease, axonal, type 2A2B; Hereditary motor and sensory neuropathy VIA |
MIP |
Cataract 15, multiple types |
MLYCD |
Malonyl-CoA decarboxylase deficiency |
MMAA |
Methylmalonic aciduria, vitamin B12-responsive, cblA type |
MMAB |
Methylmalonic aciduria, vitamin B12-responsive, cblB type |
MMACHC |
Methylmalonic aciduria and homocystinuria, cblC type |
MMADHC |
Homocystinuria, cblD type, variant 1; Methylmalonic aciduria and homocystinuria, cblD type; Methylmalonic aciduria, cblD type, variant 2 |
MMUT |
Methylmalonic aciduria, mut(0) type |
MOCS1 |
Molybdenum cofactor deficiency A |
MPV17 |
Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) |
MRPL3 |
Combined oxidative phosphorylation deficiency 9 |
MRPL44 |
Combined oxidative phosphorylation deficiency 16 |
MRPS16 |
Combined oxidative phosphorylation deficiency 2 |
MRPS22 |
Combined oxidative phosphorylation deficiency 5 |
MRPS7 |
Combined oxidative phosphorylation deficiency 34 |
MSRB3 |
Deafness, autosomal recessive 74 |
MTFMT |
Combined oxidative phosphorylation deficiency 15 |
MTO1 |
Combined oxidative phosphorylation deficiency 10 |
MTPAP |
Spastic ataxia 4, autosomal recessive |
MTRR |
Homocystinuria-megaloblastic anemia, cbl E type; {Neural tube defects, folate-sensitive, susceptibility to} |
NADK2 |
2,4-dienoyl-CoA reductase deficiency |
NAGS |
N-acetylglutamate synthase deficiency |
NARS2 |
Combined oxidative phosphorylation deficiency 24; Deafness, autosomal recessive 94 |
NBAS |
Infantile liver failure syndrome 2; Short stature, optic nerve atrophy, and Pelger-Huet anomaly |
NDUFA1 |
Mitochondrial complex I deficiency |
NDUFA10 |
Leigh syndrome |
NDUFA11 |
Mitochondrial complex I deficiency |
NDUFA12 |
Leigh syndrome due to mitochondrial complex 1 deficiency |
NDUFA2 |
Leigh syndrome due to mitochondrial complex I deficiency |
NDUFA9 |
Mitochondrial complex I deficiency, nuclear type 26 |
NDUFA9 |
Mitochondrial complex I deficiency, nuclear type 26 |
NDUFAF1 |
Mitochondrial complex I deficiency |
NDUFAF2 |
Mitochondrial complex I deficiency |
NDUFAF3 |
Mitochondrial complex I deficiency |
NDUFAF4 |
Mitochondrial complex I deficiency |
NDUFAF5 |
Mitochondrial complex 1 deficiency |
NDUFAF6 |
Mitochondrial complex I deficiency, nuclear type 17 |
NDUFB11 |
?Mitochondrial complex I deficiency, nuclear type 30; Linear skin defects with multiple congenital anomalies 3 |
NDUFB11 |
Mitochondrial complex I deficiency, nuclear type 30; Linear skin defects with multiple congenital anomalies 3 |
NDUFB3 |
Mitochondrial complex I deficiency |
NDUFB9 |
Mitochondrial complex I deficiency |
NDUFS1 |
Mitochondrial complex I deficiency |
NDUFS2 |
Mitochondrial complex I deficiency |
NDUFS3 |
Leigh syndrome due to mitochondrial complex I deficiency; Mitochondrial complex I deficiency |
NDUFS4 |
Leigh syndrome; Mitochondrial complex I deficiency |
NDUFS6 |
Mitochondrial complex I deficiency |
NDUFS7 |
Leigh syndrome |
NDUFS8 |
Leigh syndrome due to mitochondrial complex I deficiency |
NDUFV1 |
Mitochondrial complex I deficiency |
NDUFV2 |
Mitochondrial complex I deficiency |
NFU1 |
Multiple mitochondrial dysfunctions syndrome 1 |
NNT |
Glucocorticoid deficiency 4, with or without mineralocorticoid deficiency |
NR2F1 |
Bosch-Boonstra-Schaaf optic atrophy syndrome |
NTHL1 |
Familial adenomatous polyposis 3 |
NUBPL |
Mitochondrial complex I deficiency |
OAT |
Gyrate atrophy of choroid and retina with or without ornithinemia |
OGDH |
?Oxoglutarate dehydrogenase deficiency |
OGG1 |
Renal cell carcinoma, clear cell, somatic |
OPA1 |
Mitochondrial DNA depletion syndrome 14; Behr syndrome; Optic atrophy 1; Optic atrophy plus syndrome |
OPA3 |
3-methylglutaconic aciduria, type III; Optic atrophy 3 with cataract |
OTC |
Ornithine transcarbamylase deficiency |
OTC |
Ornithine transcarbamylase deficiency |
OXCT1 |
Succinyl CoA:3-oxoacid CoA transferase deficiency |
P4HB |
Cole-Carpenter syndrome 1 |
PAM16 |
Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type |
PANK2 |
HARP syndrome; Neurodegeneration with brain iron accumulation 1 |
PARK7 |
Parkinson disease 7, autosomal recessive early-onset |
PARS2 |
Epileptic encephalopathy, early infantile, 75 |
PC |
Pyruvate carboxylase deficiency |
PC |
Pyruvate carboxylase deficiency |
PCCA |
Propionicacidemia |
PCCA |
Propionicacidemia |
PCCB |
Propionicacidemia |
PCCB |
Propionicacidemia |
PCK2 |
PEPCK deficiency, mitochondrial |
PDHA1 |
Pyruvate dehydrogenase E1-alpha deficiency |
PDHB |
Pyruvate dehydrogenase E1-beta deficiency |
PDHX |
Lacticacidemia due to PDX1 deficiency |
PDK3 |
?Charcot-Marie-Tooth disease, X-linked dominant, 6 |
PDP1 |
Pyruvate dehydrogenase phosphatase deficiency |
PDSS1 |
Coenzyme Q10 deficiency, primary, 2 |
PDSS2 |
Coenzyme Q10 deficiency, primary, 3 |
PDX1 |
MODY, type IV; Pancreatic agenesis 1 |
PET100 |
Mitochondrial complex IV deficiency |
PEX11B |
Peroxisome biogenesis disorder 14B |
PHYH |
Refsum disease |
PINK1 |
Parkinson disease 6, early onset |
PKLR |
Adenosine triphosphate, elevated, of erythrocytes; Pyruvate kinase deficiency |
PNPLA8 |
?Mitochondrial myopathy with lactic acidosis |
PNPO |
Pyridoxamine 5′-phosphate oxidase deficiency |
PNPT1 |
Combined oxidative phosphorylation deficiency 13; Deafness, autosomal recessive 70 |
PNPT1 |
Combined oxidative phosphorylation deficiency 13; Deafness, autosomal recessive 70 |
POLG |
Mitochondrial DNA depletion syndrome 4A (Alpers type); Mitochondrial DNA depletion syndrome 4B (MNGIE type); Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE); Progressive external ophthalmoplegia, autosomal dominant 1; Progressive external ophthalmoplegia, autosomal recessive 1 |
POLG2 |
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4 |
PPOX |
Porphyria variegata |
PRODH |
Hyperprolinemia, type I; {Schizophrenia, susceptibility to, 4} |
PTRH2 |
Infantile-onset multisystem neurologic, endocrine, and pancreatic disease |
PTS |
Hyperphenylalaninemia, BH4-deficient, A |
PUS1 |
Myopathy, lactic acidosis, and sideroblastic anemia 1 |
PYCR1 |
Cutis laxa, autosomal recessive, type IIB; Cutis laxa, autosomal recessive, type IIIB |
PYCR2 |
Leukodystrophy, hypomyelinating, 10 |
QDPR |
Hyperphenylalaninemia, BH4-deficient, C |
RARS2 |
Pontocerebellar hypoplasia, type 6 |
RDH11 |
?Retinal dystrophy, juvenile cataracts, and short stature syndrome |
REEP1 |
Neuronopathy, distal hereditary motor, type VB; Spastic paraplegia 31, autosomal dominant |
RMND1 |
Combined oxidative phosphorylation deficiency 11 |
RMND1 |
Combined oxidative phosphorylation deficiency 11 |
RNASEH1 |
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2 |
RNASEL |
Prostate cancer 1 |
RPIA |
Ribose 5-phosphate isomerase deficiency |
RPL35A |
Diamond-Blackfan anemia 5 |
RPS14 |
Macrocytic anemia, refractory, due to 5q deletion, somatic |
RRM2B |
Mitochondrial DNA depletion syndrome 8A; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5 |
SARS2 |
Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis |
SCO1 |
Mitochondrial complex IV deficiency |
SCO2 |
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1; Myopia 6 |
SDHA |
Mitochondrial respiratory chain complex II deficiency; Leigh syndrome; Cardiomyopathy, dilated, 1GG; Paragangliomas 5 |
SDHAF1 |
Mitochondrial complex II deficiency |
SDHAF2 |
Paragangliomas 2 |
SECISBP2 |
Thyroid hormone metabolism, abnormal |
SERAC1 |
3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome |
SERAC1 |
3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome |
SETX |
Amyotrophic lateral sclerosis 4, juvenile; Spinocerebellar ataxia, autosomal recessive 1 |
SFXN4 |
Combined oxidative phosphorylation deficiency 18 |
SFXN4 |
Combined oxidative phosphorylation deficiency 18 |
SLC16A1 |
Erythrocyte lactate transporter defect; Hyperinsulinemic hypoglycemia, familial, 7; Monocarboxylate transporter 1 deficiency |
SLC19A3 |
Thiamine metabolism dysfunction syndrome 2 |
SLC25A12 |
Developmental and epileptic encephalopathy 39 |
SLC25A13 |
Citrullinemia, adult-onset type II; Citrullinemia, type II, neonatal-onset |
SLC25A15 |
Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome |
SLC25A19 |
Microcephaly, Amish type; Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type) |
SLC25A20 |
Carnitine-acylcarnitine translocase deficiency |
SLC25A22 |
Developmental and epileptic encephalopathy 3 |
SLC25A26 |
Combined oxidative phosphorylation deficiency 28 |
SLC25A3 |
Mitochondrial phosphate carrier deficiency |
SLC25A3 |
Mitochondrial phosphate carrier deficiency |
SLC25A38 |
Anemia, sideroblastic, 2, pyridoxine-refractory |
SLC25A4 |
Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD; Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2 |
SLC25A46 |
Neuropathy, hereditary motor and sensory, type VIB |
SLC37A4 |
Glycogen storage disease Ib; Glycogen storage disease Ic |
SLC6A8 |
Cerebral creatine deficiency syndrome 1 |
SLC9A6 |
Intellectual developmental disorder, X-linked syndromic, Christianson type |
SNAP29 |
Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome |
SOD1 |
Amyotrophic lateral sclerosis 1 |
SOD2 |
{Microvascular complications of diabetes 6} |
SPAST |
Spastic paraplegia 4, autosomal dominant |
SPG7 |
Spastic paraplegia 7, autosomal recessive |
SPR |
Dystonia, dopa-responsive, due to sepiapterin reductase deficiency |
SPTLC2 |
Neuropathy, hereditary sensory and autonomic, type IC |
SUCLA2 |
Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria) |
SUCLA2 |
Mitochondrial DNA depletion syndrome 5 |
SUCLG1 |
Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria) |
SUCLG1 |
Mitochondrial DNA depletion syndrome 9 |
SUGCT |
Glutaric aciduria III |
SUOX |
Sulfite oxidase deficiency |
SURF1 |
Charcot-Marie-Tooth disease, type 4K; Mitochondrial complex IV deficiency, nuclear type 1 |
SURF1 |
Charcot-Marie-Tooth disease, type 4K; Leigh syndrome, due to COX IV deficiency |
TACO1 |
Mitochondrial complex IV deficiency |
TARS2 |
Combined oxidative phosphorylation deficiency 21 |
TAZ |
Barth syndrome |
TCIRG1 |
Osteopetrosis, autosomal recessive 1 |
TFAM |
Mitochondrial DNA depletion syndrome 15 |
TFR2 |
Hemochromatosis, type 3 |
TIMM8A |
Mohr-Tranebjaerg syndrome |
TK2 |
Mitochondrial DNA depletion syndrome 2; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3 |
TMEM126A |
Optic atrophy 7 |
TMEM126B |
Mitochondrial complex I deficiency, nuclear type 29 |
TMEM70 |
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2 |
TMLHE |
{Autism, susceptibility to, X-linked 6} |
TPI1 |
Hemolytic anemia due to triosephosphate isomerase deficiency |
TPK1 |
Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type) |
TRIT1 |
Combined oxidative phosphorylation deficiency 35 |
TRMT10C |
Combined oxidative phosphorylation deficiency 30 |
TRMU |
Liver failure, transient infantile; Deafness, mitochondrial, modifier of |
TRNT1 |
Retinitis pigmentosa and erythrocytic microcytosis; Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay |
TSFM |
Combined oxidative phosphorylation deficiency 3 |
TTC19 |
Mitochondrial complex III deficiency, nuclear type 2 |
TUBB3 |
Cortical dysplasia, complex, with other brain malformations 1; Fibrosis of extraocular muscles, congenital, 3A |
TUFM |
Combined oxidative phosphorylation deficiency 4 |
TWNK |
Mitochondrial DNA depletion syndrome 7; Perrault syndrome 5; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3 |
TYMP |
Mitochondrial DNA depletion syndrome 1 (MNGIE type) |
UNG |
Immunodeficiency with hyper IgM, type 5 |
UQCC2 |
Mitochondrial complex III deficiency, nuclear type 7 |
UQCC3 |
Mitochondrial complex III deficiency, nuclear type 9 |
UQCRB |
Mitochondrial complex III deficiency, nuclear type 3 |
UQCRC2 |
Mitochondrial complex III deficiency, nuclear type 5 |
UQCRQ |
Mitochondrial complex III deficiency, nuclear type 4 |
VARS2 |
Combined oxidative phosphorylation deficiency 20 |
WDR81 |
Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2; Hydrocephalus, congenital, 3, with brain anomalies |
WFS1 |
Deafness, autosomal dominant 6/14/38; Wolfram syndrome 1; Wolfram-like syndrome, autosomal dominant; Cataract 41; Diabetes mellitus, noninsulin-dependent, association with |
XPNPEP3 |
Nephronophthisis-like nephropathy 1 |
YARS2 |
Myopathy, lactic acidosis, and sideroblastic anemia 2 |